To the full analysis
Immunocore Holdings stock: growth
IMCRImmunocore Holdings reported $400.02M in revenue for fiscal 2025, up 28.8% on the prior year, up 198.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
55.2%
per year from 2013 to 2025
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 67.7% | 42.7% | 55.2% |
| Revenue per share | 53.0% | no data | no data |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $2.04M | −$3.69M | $10.69M |
| 2014 | $6.38M | −$5.59M | $37.76M |
| 2015 | $11.46M | $13.45M | −$23.71M |
| 2016 | $16.46M | −$23.13M | −$43.08M |
| 2017 | $14.45M | −$49.57M | −$79.46M |
| 2018 | $23.65M | −$71.63M | −$20.16M |
| 2019 | $25.67M | −$103.93M | −$105.65M |
| 2020 | $30.11M | −$74.09M | −$63.65M |
| 2021 | $27.04M | −$133.45M | −$144.49M |
| 2022 | $144.23M | −$43.46M | −$51.41M |
| 2023 | $197.39M | −$43.75M | −$1.97M |
| 2024 | $310.48M | −$51.09M | $20.89M |
| 2025 | $400.02M | −$35.51M | −$15.05M |
Revenue by region
Where Immunocore Holdings plc generates its revenue.
- United States$257.0M64%
- Europe$131.4M33%
- Rest of world$11.6M3%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $257M | 64.2% |
| Europe | $131.42M | 32.9% |
| Rest of world | $11.6M | 2.9% |
| Total revenue | $400.02M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.